Currently, small-molecule drug discovery is a long and costly process. AI-enabled virtual screening is the latest advance in accelerating the process. Computational screening provides a feasible trajectory to fully explore and interrogate the expansive universe of chemical compounds capable of binding protein targets of clinical interest.
X-37 uses AtomNet, an AI algorithm developed by Atomwise, to identify chemicals with drug-like structures to accelerate the drug discovery process for difficult-to-target proteins — often characterized as undruggable.
X-37 combines the power of AtomNet with the capabilities of a team of seasoned and successful drug developers to bring promising small molecules into clinical development.